文献速递乳腺癌

奥拉帕利联合同期放疗治疗三阴性乳腺癌:奥拉帕利与放疗治疗三阴性乳腺癌1期试验

Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
PubMed 文献 · JAMA Oncol · 2022-01-01

这项1期前瞻性剂量递增试验自2017年9月至2019年11月纳入24例新辅助化疗后病理反应不全或不可切除的三阴性乳腺癌患者,奥拉帕利与放疗同期给予。未观察到剂量限制性毒性,奥拉帕利递增至200 mg每日两次未达最大耐受剂量;3年总生存率为83%(95%CI,70%-100%),无事件生存率为65%(95%CI,48%-88%)。作者认为该方案耐受良好,应继续在进一步临床试验中评估。

要点

  • 24例三阴性乳腺癌患者接受奥拉帕利(50-200 mg每日两次)联合同期放疗,未观察到剂量限制性毒性。
  • 奥拉帕利递增至200 mg每日两次未达最大耐受剂量,2年随访时最大治疗相关毒性为1例(4.2%)2级乳房疼痛、纤维化和畸形。
  • 3年总生存率为83%(95%CI,70%-100%),无事件生存率为65%(95%CI,48%-88%)。

核心结论

  • 这项1期剂量递增试验的结果提示,奥拉帕利抑制PARP联合同期放疗治疗早期高危三阴性乳腺癌耐受良好,应继续在进一步临床试验中评估。

研究设计与样本

  • 这项1期前瞻性剂量递增试验(RadioPARP试验)采用至事件时间持续重新评估法,于2017年9月至2019年11月进行,随访至2021年11月。
  • 纳入24例患者(100%女性;中位年龄46岁[范围25-74岁]),为新辅助化疗后病理反应不全或虽经新辅助化疗仍不可切除的三阴性乳腺癌患者,美国东部肿瘤协作组体能状态评分为0或1分,器官功能充分。

主要发现

  • 24例患者中未观察到剂量限制性毒性,奥拉帕利递增至200 mg每日两次未达最大耐受剂量。
  • 未观察到晚期治疗相关3级或以上毒性,2年随访时观察到的最大治疗相关毒性为1例患者(4.2%)的2级乳房疼痛、纤维化和畸形。
  • 3年总生存率为83%(95%CI,70%-100%),3年无事件生存率为65%(95%CI,48%-88%)。
  • 同源重组状态与总生存率或无事件生存率无关。

临床怎么用

  • 作者认为,奥拉帕利联合同期放疗治疗早期高危三阴性乳腺癌耐受良好,应继续在进一步临床试验中评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Triple-negative breast cancer (TNBC) cells are sensitive to poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors used as radiosensitizers. Whether combining PARP inhibitors with radiotherapy in patients with TNBC would enhance the biological effectiveness of the irradiation and improve locoregional control is unclear. OBJECTIVE: To assess the safety and tolerability of PARP inhibition with olaparib used concurrently with radiotherapy in patients with TNBC with residual disease after neoadjuvant chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: This phase 1 prospective dose-escalation trial (Olaparib and Radiation Therapy for TNBC [RadioPARP] trial) using a time-to-event continual reassessment method was performed from September 2017 to November 2019, with follow-up until November 2021. Participants had an incomplete pathologic response after neoadjuvant chemotherapy or unresectable TNBC despite previous neoadjuvant chemotherapy, an Eastern Cooperative Oncology Group Performance Status score of 0 or 1, and adequate organ functions. INTERVENTIONS: Olaparib was administered orally in the form of tablets and given at increasing doses (50 mg, 100 mg, 150 mg, or 200 mg twice daily). Olaparib therapy was started 1 week before radiotherapy and was continued concomitantly with radiotherapy. After breast-conserving surgery, a total dose of 50.4 Gy was delivered to the whole breast, with a 63-Gy simultaneously integrated boost to the tumor bed for patients younger than 60 years. After radical mastectomy or for unresectable tumors despite neoadjuvant chemotherapy, a total dose of 50.0 Gy was delivered to the chest wall (after mastectomy) or to the whole breast (for unresectable tumors). Regional lymph node stations could be treated with a total dose of 50.0 Gy to 50.4 Gy in cases of node-positive disease. MAIN OUTCOMES AND MEASURES: Main outcomes were the safety and tolerability of PARP inhibition with radiotherapy for early-stage, high-risk TNBC. Secondary outcomes included overall survival (OS) and event-free survival (EFS). RESULTS: Among the 24 patients included in the trial (100% female; median age, 46 years [range, 25-74 years]), no dose-limiting toxic effects were observed, and olaparib was escalated to 200 mg twice daily without reaching the maximum tolerated dose. No late treatment-related grade 3 or greater toxic effect was observed, and the maximum observed treatment-related toxic effects at the 2-year follow-up were grade 2 breast pain, fibrosis, and deformity in 1 patient (4.2%). Three-year OS and EFS were 83% (95% CI, 70%-100%) and 65% (95% CI, 48%-88%), respectively. Homologous recombination status was not associated with OS or EFS. CONCLUSIONS AND RELEVANCE: The findings of this phase 1 dose-escalation trial suggest that PARP inhibition with olaparib concurrently with radiotherapy for early-stage, high-risk TNBC is well tolerated and should continue to be evaluated in further clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03109080.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Loap P, Loirat D, Berger F, et al. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. JAMA Oncol. 2022. PMID: 36301572. doi:10.1001/jamaoncol.2022.5074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。